Acta Chim. Sinica ›› 2015, Vol. 73 ›› Issue (4): 349-356.DOI: 10.6023/A15010055 Previous Articles     Next Articles



杜征臻a, 张琰a, 叶金海b, 徐衡c, 郎美东a   

  1. a 上海市先进聚合物材料重点实验室 超细材料制备与应用教育部重点实验室 华东理工大学材料科学与工程学院 上海 200237;
    b 南京医科大学 口腔医学院 南京 210029;
    c 安徽省石油化工新材料协同创新中心 安庆师范学院化学化工学院 安庆 246011
  • 投稿日期:2015-01-20 发布日期:2015-01-28
  • 通讯作者: 张琰, 郎美东;
  • 基金资助:

    项目受国家自然科学基金(Nos. 21274039, 81371123)、上海市浦江人才计划(No. 14PJD014)和上海市基础研究重点(Nos. 12JC1403000, 12JC1403100)资助.

Synthesis and Properties of the Poly(ε-caprolactone)-paclitaxel Prodrug

Du Zhengzhena, Zhang Yana, Ye Jinhaib, Xu Hengc, Lang Meidonga   

  1. a Shanghai Key Laboratory of Advanced Polymeric Materials, Key Laboratory for Ultrafine Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai 200237;
    b Institute of Stomatology, School of Stomatology, Nanjing Medical University, Nanjing 210029;
    c Anhui Collaborative Innovation Center for Petrochemical New Materials, School of Chemistry and Chemical Engineering, Anqing Normal University, Anqing 246011
  • Received:2015-01-20 Published:2015-01-28
  • Supported by:

    Project supported by the National Natural Science Foundation of China (Nos. 21274039, 81371123), the Shanghai Pujiang Program (No. 14PJD014) and the Basic Research Key Program Project of Commission of Science and Technology of Shanghai (Nos. 12JC1403000, 12JC1403100).

This study presents a paclitaxel (PTX) based polymeric prodrug (FCPTX) using functionalized Pluronic-b-poly(ε-caprolactone) bearing carboxyl groups [pluronic-b-poly(ε-caprolactone-co-6-carboxylic-ε-caprolactone), Pluronic-b-P(CL-co-CCL), FC] as the substrate by a dicyclohexylcarbodiimide/4-dimethylaminopyridine-catalyzed (DCC/DMAP-catalyzed) esterification reaction. High Performance Liquid Chromatography (HPLC) and 1H NMR were employed together to prove the successful reaction and confirmed the structure and composition of FCPTX. The result revealed that the 2'-OH of PTX participated in reaction and the PTX content in FCPTX was up to 18.3 wt%. The polymeric prodrug could self-assemble into micelles via an emulsion/solvent evaporation technique. Furthermore, the micelle was used as the nanomicellar carrier for delivery of free PTX. TEM and DLS were used to study the size and morphologies of the FCPTX micelles and PTX-loaded FCPTX (PTX/FCPTX) micelles. The results demonstrated that the two micelles were spherical spheres with narrow distribution and the size of PTX/FCPTX micelles was larger than that of FCPTX micelles due to the micellar core was enlarged by the loaded drug. The drug loading content (DLC) and drug loading efficiency (DLE) demonstrated that the great drug loading capability of FCPTX for free PTX which could be attributed to the fact that the excellent compatibility between drug and micellar core. The sustained in vitro release of PTX/FCPTX was due to that the forceful intermolecular interaction between conjugated PTX on the polymer and the encapsulated PTX, also, the forceful intermolecular interaction led to the high residual of PTX (only 33.0% total release after 72 h at pH 7.4). However, in the lower pH environment, the drug release was accelerated due to hydrolysis of ester bond and disaggregation of micelles. In vitro antitumor experiments showed that the cytotoxicity of the conjugated PTX was reduced due to that the 2'-OH of PTX was reacted and the drug activity was crippled. The PTX/FCPTX micelles revealed high antitumor activity due to the high cellular accumulation by micelle delivery. Subsequently, the great blood compatibility of FCPTX micelles and PTX/FCPTX micelles were obtained. All of the results demonstrated the use of the polymeric conjugated PTX as the core of the polymeric micelles afforded an ideal affinity site for free PTX and had a marvelous potential in combination chemotherapy.

Key words: ε-caprolactone, polymeric prodrug, paclitaxel, micelle